Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,010 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Pulmonary Diseases Clear all
Completed Phase 3 Interventional

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

NCT00649025
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
21
States / cities
Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 10, 2026, 4:41 PM EDT
Suspended Phase 1 Interventional

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

NCT01604863
View directory record Official record
Conditions
Cancer
Interventions
HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Scottsdale, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT06843239
View directory record Official record
Conditions
Systemic Sclerosis (SSc), Scleroderma
Interventions
Tibulizumab, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

NCT00825487
View directory record Official record
Conditions
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Interventions
ARQ 621
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Phoenix, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting No phase listed Observational

Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

NCT04968548
View directory record Official record
Conditions
Lung Cancer
Interventions
Blood collection
Procedure
Lead sponsor
Nucleix Ltd.
Industry
Eligibility
50 Years to 80 Years
Enrollment
5,000 participants
Timeline
2021 – 2025
U.S. locations
27
States / cities
Encinitas, California • Lakewood, Colorado • West Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated No phase listed Observational

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00008216
View directory record Official record
Conditions
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Peripheral Blood Stem Cell Transplantation
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 10, 2026, 4:41 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

NCT04832932
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
COVID-19 vaccines
Biological
Lead sponsor
Mebo Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Miami, Florida • Vonore, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
BNT326, Pumitamig
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT00658086
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, normal saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 Molecular OTC At Home Test

NCT05704803
View directory record Official record
Conditions
COVID-19 Pandemic
Interventions
Diagnostic Test: IN Vitro
Diagnostic Test
Lead sponsor
3EO Health
Industry
Eligibility
2 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Humble, Texas • Kingwood, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional

SUNLIGHT Study: Online Support Groups for MS to Address COVID-19

NCT04379661
View directory record Official record
Conditions
MS (Multiple Sclerosis), COVID-19, Support Groups
Interventions
Online support Group
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting Phase 1 Interventional

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02495896
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions
Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 10, 2026, 4:41 PM EDT
Not yet recruiting Not applicable Interventional

PRECISION-CPR: PRecision-Controlled Ventilation in CPR

NCT07088120
View directory record Official record
Conditions
Cardiac Arrest (CA)
Interventions
Precision-Controlled Ventilation with Real-Time Feedback, Standard Manual Ventilation During CPR
Device · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

NVA237 Versus Placebo 12-week Efficacy Study

NCT01709864
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
54
States / cities
Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of SLV213 for the Treatment of COVID-19.

NCT06146374
View directory record Official record
Conditions
COVID-19
Interventions
Placebo for SLV213, SLV213
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

NCT06744374
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BGF, MITT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
22,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

NCT05594615
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Midazolam, Rosuvastatin, Caffeine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

NCT02608268
View directory record Official record
Conditions
Advanced Malignancies
Interventions
MBG453, PDR001, Decitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 1 Interventional

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT04678648
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Interventions
RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
Drug
Lead sponsor
RasCal Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

12-Week Study in Adult Subjects With Asthma

NCT01516073
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 10, 2026, 4:41 PM EDT
Withdrawn Phase 4 Interventional

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

NCT03949842
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 10, 2026, 4:41 PM EDT